Finance

Lists
Why is AKTS down 4,46%?
Dive Deeper
AKTS:NASDAQ
Aktis Oncology Inc
17,34 $
-4,46%
(-0,81) 1D
17,34 $
0,00% (0,00)
After hours
Closed: 12 հոկ, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AKTS...
Open
18,12 $
High
18,19 $
Low
17,31 $
Mkt. cap
931,97 մլն
Avg. vol.
431,66 հզր
Volume
274,07 հզր
52-wk high
34,19 $
52-wk low
14,72 $
EPS
-1,42 $
Shares outstanding
53,75 մլն
No. of employees
79
Open
18,12 $
High
18,19 $
Low
17,31 $
Mkt. cap
931,97 մլն
Avg. vol.
431,66 հզր
Volume
274,07 հզր
52-wk high
34,19 $
52-wk low
14,72 $
EPS
-1,42 $
Shares outstanding
53,75 մլն
No. of employees
79
News stories
From web sources and news partners
About Aktis Oncology Inc
CEO-
Employees79
Founded2020
HeadquartersԲոստոն, Մասսաչուսեթս, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to AKTS in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AKTS in the last 3 months.
Highest
Current 17,34 $
40,00 $ (+130,68%)
Average
35,80 $ (+106,46%)
Lowest
33,00 $ (+90,31%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Nierengarten
Wedbush
Buy
Maintained
35,00 $
+101,8%
10/02/2026
Jeff Jones
Oppenheimer
Buy
Initiated
40,00 $
+130,7%
09/09/2026
David Lebowitz
BMO Capital
Buy
Initiated
37,00 $
+113,4%
08/18/2026
Unknown Analyst
BMO Capital
Buy
Initiated
37,00 $
+113,4%
08/18/2026
Alec Stranahan
Bank of America Securities
Buy
Maintained
34,00 $
+96,1%
08/14/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
33,00 $
+90,3%
08/14/2026
Alexandra Ramsey
William Blair
Buy
Maintained
-
-
08/14/2026
Christopher Raymond
Raymond James
Buy
Initiated
40,00 $
+130,7%
06/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
35,00 $
+101,8%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Sami Corwin
William Blair
Buy
Initiated
18,75 $
+8,1%
05/02/2026
Unknown Analyst
William Blair
Buy
Initiated
18,60 $
+7,3%
04/29/2026
Andy Hsieh
William Blair
Buy
Initiated
32,00 $
+84,5%
04/29/2026
Jonathan Chang
Leerink Partners
Buy
Initiated
31,00 $
+78,8%
02/03/2026
Last report
13 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,44 $ / -0,43 $
-2,15%miss
Revenue / Est. (USD)
3,38 մլն / 2,58 մլն
+30,99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. հնս
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
1,60 մլն
1,87 մլն
3,23 մլն
3,38 մլն
Cost of goods sold
18,63 մլն
16,49 մլն
20,04 մլն
25,28 մլն
Cost of revenue
18,63 մլն
16,49 մլն
20,04 մլն
25,28 մլն
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,94 մլն
2,75 մլն
5,90 մլն
7,00 մլն
Operating expense
3,94 մլն
2,75 մլն
5,90 մլն
7,00 մլն
Total operating expenses
22,56 մլն
19,24 մլն
25,93 մլն
32,28 մլն
Operating income
-20,96 մլն
-17,38 մլն
-22,71 մլն
-28,90 մլն
Other non operating income
-20,00 հզր
-11,00 հզր
-3,00 հզր
-10,00 հզր
EBT including unusual items
-18,08 մլն
-15,14 մլն
-18,32 մլն
-24,14 մլն
EBT excluding unusual items
-18,08 մլն
-15,14 մլն
-18,32 մլն
-24,14 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-18,08 մլն
-15,14 մլն
-18,32 մլն
-24,14 մլն
Net profit margin
-1 128,98%
-809,52%
-567,86%
-713,48%
Earnings per share
-
-
-0,38
-0,44
Interest and investment income
2,91 մլն
2,25 մլն
4,38 մլն
4,76 մլն
Interest expense
-
-
-
-
Net interest expenses
2,91 մլն
2,25 մլն
4,38 մլն
4,76 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-20,41 մլն
-16,68 մլն
-22,05 մլն
-28,02 մլն
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps